Vilsbøll, Tina

Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes

Marso, S. P., Bain, S. C., Consoli, A., Eliaschewitz, F. G., Jódar, E., Leiter, L. A., Lingvay, I., Rosenstock, J., Seufert, J., Warren, M. L., et al. (2016) · New England Journal of Medicine

Diabetes Treatment and ManagementDiabetes, Cardiovascular Risks, and Lipoproteins

Cited by 6,900

Oral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes

Husain, M., Birkenfeld, A. L., Donsmark, M., Dungan, K., Eliaschewitz, F. G., Franco, D. R., Jeppesen, O. K., Lingvay, I., Mosenzon, O., Pedersen, S. D., et al. (2019) · New England Journal of Medicine

Diabetes Treatment and ManagementDiabetes, Cardiovascular Risks, and Lipoproteins

Cited by 1,997

Recovery of gut microbiota of healthy adults following antibiotic exposure

Palleja, A., Mikkelsen, K. H., Forslund, S. K., Kashani, A., Allin, K. H., Nielsen, T., Hansen, T. H., Liang, S., Feng, Q., Zhang, C., et al. (2018) · Nature Microbiology

Gut microbiota and healthAntibiotic Resistance in Bacteria

Cited by 875

Glucagon-like peptide 1 in health and disease

Andersen, A., Lund, A., Knop, F. K., & Vilsbøll, T. (2018) · Nature Reviews Endocrinology

Diabetes Treatment and ManagementDiabetes Management and Research

Cited by 543

Incretin secretion in relation to meal size and body weight in healthy subjects and people with type 1 and type 2 diabetes mellitus

Vilsbøll, T., Krarup, T., Sonne, J., Madsbad, S., Vølund, A., Juul, A. G., & Holst, J. J. (2003) · The Journal of Clinical Endocrinology & Metabolism

Diabetes Treatment and ManagementPancreatic function and diabetes

Cited by 528

Similar elimination rates of glucagon-like peptide-1 in obese type 2 diabetic patients and healthy subjects

Vilsbøll, T., Agersø, H., Krarup, T., & Holst, J. J. (2003) · The Journal of Clinical Endocrinology & Metabolism

Diabetes Treatment and ManagementPancreatic function and diabetes

Cited by 444

Both GLP-1 and GIP are insulinotropic at basal and postprandial glucose levels and contribute nearly equally to the incretin effect of a meal in healthy subjects

Vilsbøll, T., Krarup, T., Madsbad, S., & Holst, J. J. (2003) · Regulatory Peptides

Diabetes Treatment and ManagementPancreatic function and diabetes

Cited by 430

Four weeks of near-normalisation of blood glucose improves the insulin response to glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide in patients with type 2 diabetes

Højberg, P. V., Vilsbøll, T., Rabøl, R., Knop, F. K., Bache, M., Krarup, T., Holst, J. J., & Madsbad, S. (2009) · Diabetologia

Diabetes Treatment and ManagementPancreatic function and diabetes

Cited by 414

Glucose-Dependent Insulinotropic Polypeptide

Christensen, M., Vedtofte, L., Holst, J. J., Vilsbøll, T., & Knop, F. K. (2011) · Diabetes

Pancreatic function and diabetesDiabetes Treatment and Management

Cited by 353

Reduced Incretin Effect in Type 2 Diabetes

Knop, F. K., Vilsbøll, T., Højberg, P. V., Larsen, S., Madsbad, S., Vølund, A., Holst, J. J., & Krarup, T. (2007) · Diabetes

Pancreatic function and diabetesDiabetes Treatment and Management

Cited by 349

Semaglutide, reduction in glycated haemoglobin and the risk of diabetic retinopathy

Vilsbøll, T., Bain, S. C., Leiter, L. A., Lingvay, I., Matthews, D., Simó, R., Helmark, I. C., Wijayasinghe, N., & Larsen, M. (2018) · Diabetes, Obesity and Metabolism

Diabetes Treatment and ManagementRetinal Diseases and Treatments

Cited by 318

Efficacy and safety of sitagliptin when added to insulin therapy in patients with type 2 diabetes

Vilsbøll, T., Rosenstock, J., Yki‐Järvinen, H., Cefalu, W. T., Chen, Y., Luo, E., Musser, B., Andryuk, P. J., Ling, Y., Kaufman, K. D., et al. (2010) · Diabetes, Obesity and Metabolism

Diabetes Treatment and ManagementDiabetes Management and Research

Cited by 305

The glucagonostatic and insulinotropic effects of glucagon-like peptide 1 contribute equally to its glucose-lowering action

Hare, K. J., Vilsbøll, T., Asmar, M., Deacon, C. F., Knop, F. K., & Holst, J. J. (2010) · Diabetes

Diabetes Treatment and ManagementPancreatic function and diabetes

Cited by 276

Exenatide once weekly for alcohol use disorder investigated in a randomized, placebo-controlled clinical trial

Klausen, M. K., Jensen, M. E., Møller, M., Le Dous, N., Jensen, A.-M. Ø., Zeeman, V. A., Johannsen, C.-F., Lee, A., Thomsen, G. K., Macoveanu, J., et al. (2022) · JCI Insight

Substance Abuse Treatment and OutcomesNeurotransmitter Receptor Influence on Behavior

Cited by 262

Contribution of liraglutide in the fixed-ratio combination of insulin degludec and liraglutide (IDegLira)

Buse, J. B., Vilsbøll, T., Thurman, J., Blevins, T. C., Langbakke, I. H., Bøttcher, S. G., & Rodbard, H. W. (2014) · Diabetes Care

Diabetes Treatment and ManagementDiabetes Management and Research

Cited by 259

Secretion of glucagon-like peptide-1 in patients with type 2 diabetes mellitus: systematic review and meta-analyses of clinical studies

Calanna, S., Christensen, M., Holst, J. J., Laferrère, B., Gluud, L. L., Vilsbøll, T., & Knop, F. K. (2013) · Diabetologia

Diabetes Treatment and ManagementPancreatic function and diabetes

Cited by 251

Effect of Liraglutide Treatment on Prediabetes and Overweight or Obesity in Clozapine- or Olanzapine-Treated Patients With Schizophrenia Spectrum Disorder: A Randomized Clinical Trial

Larsen, J. R., Vedtofte, L., Jakobsen, M. S. L., Jespersen, H. R., Jakobsen, M. I., Svensson, C. K., Koyuncu, K., Schjerning, O., Oturai, P. S., Kjaer, A., et al. (2017) · JAMA Psychiatry

Schizophrenia research and treatmentPharmacology and Obesity Treatment

Cited by 250

Impaired regulation of the incretin effect in patients with type 2 diabetes

Bagger, J. I., Knop, F. K., Lund, A., Vestergaard, H., Holst, J. J., & Vilsbøll, T. (2011) · The Journal of Clinical Endocrinology & Metabolism

Diabetes Treatment and ManagementPancreatic function and diabetes

Cited by 219

Semaglutide (SUSTAIN and PIONEER) reduces cardiovascular events in type 2 diabetes across varying cardiovascular risk

Husain, M., Bain, S. C., Jeppesen, O. K., Lingvay, I., Sørrig, R., Treppendahl, M. B., & Vilsbøll, T. (2020) · Diabetes, Obesity and Metabolism

Diabetes Treatment and ManagementHeart Failure Treatment and Management

Cited by 209

Separate and combined glucometabolic effects of endogenous glucose-dependent insulinotropic polypeptide and glucagon-like peptide 1 in healthy individuals.

Gasbjerg, L. S., Helsted, M. M., Hartmann, B., Jensen, M. H., Gabe, M. B. N., Sparre-Ulrich, A. H., Veedfald, S., Stensen, S., Lanng, A. R., Bergmann, N. C., et al. (2019) · Diabetes

Diabetes Treatment and ManagementPancreatic function and diabetes

Cited by 193

Anti-interleukin-21 antibody and liraglutide for the preservation of β-cell function in adults with recent-onset type 1 diabetes: A randomised, double-blind, placebo-controlled, phase 2 trial

von Herrath, M., Bain, S. C., Bode, B., Clausen, J. O., Coppieters, K., Gaysina, L., Gumprecht, J., Hansen, T. K., Mathieu, C., Morales, C., et al. (2021) · The Lancet Diabetes & Endocrinology

Diabetes and associated disordersPancreatic function and diabetes

Cited by 186

Metformin-Induced Glucagon-Like Peptide-1 Secretion Contributes to the Actions of Metformin in Type 2 Diabetes

Bahne, E., Sun, E. W. L., Young, R. L., Hansen, M., Sonne, D. P., Hansen, J. S., Rohde, U., Liou, A. P., Jackson, M. L., de Fontgalland, D., et al. (2018) · JCI Insight

Diabetes Treatment and ManagementMetabolism, Diabetes, and Cancer

Cited by 173

The Role of Glucagon in the Pathophysiology and Treatment of Type 2 Diabetes

Hædersdal, S., Lund, A., Knop, F. K., & Vilsbøll, T. (2018) · Mayo Clinic Proceedings

Diabetes Treatment and ManagementPancreatic function and diabetes

Cited by 162

Secretion of Glucose-Dependent Insulinotropic Polypeptide in Patients With Type 2 Diabetes

Calanna, S., Christensen, M., Holst, J. J., Laferrère, B., Gluud, L. L., Vilsbøll, T., & Knop, F. K. (2013) · Diabetes Care

Diabetes Treatment and ManagementPancreatic function and diabetes

Cited by 158